Healthcare / Diagnostics & ResearchWarsaw
$117.60
+3.40 (+2.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $51.7M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
3.1x
↓EV/EBITDA
7.4x
↓ROE
24.1%
↑Gross Margin
28.8%
↓Debt/Equity
0.45
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+17.4%
FCF CAGR
-14.4%
FCF margin
7.0%
FCF / Net income
0.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $583.8M · net income $98.5M · FCF $40.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $583.8M | $583.8M | $507.8M | $424.2M | $360.6M |
| Net Income | $98.5M | $98.5M | $96.5M | $74.2M | $44.4M |
| EBITDA | $189.1M | $189.1M | $176.4M | $151.5M | $117.7M |
| EPS | 9.40 | 9.40 | 9.20 | 7.10 | 5.17 |
| Gross Margin | 28.8% | 28.8% | 30.4% | 33.1% | 29.8% |
| Operating Margin | 23.0% | 23.0% | 25.5% | 27.7% | 24.0% |
| Net Margin | 16.9% | 16.9% | 19.0% | 17.5% | 12.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.45 | 0.45 | 0.35 | 0.43 | 0.57 |
| Current Ratio | 1.40 | 1.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $40.9M | $40.9M | $51.7M | $84.8M | $65.2M |
| Returns | |||||
| ROE | 24.1% | 24.1% | 26.8% | 25.3% | 18.4% |
| Valuation | |||||
| P/E | 3.14 | 3.14 | 13.48 | 11.07 | 8.49 |
| EV/EBITDA | 7.44 | 7.44 | 7.80 | 5.86 | 4.81 |
| P/B | 3.02 | 3.02 | 3.61 | 2.81 | 1.91 |
| Growth & Yield | |||||
| Revenue Growth | 15.0% | 15.0% | 19.7% | 17.6% | — |
| EPS Growth | 2.2% | 2.2% | 29.6% | 37.3% | — |
| Dividend Yield | 4.2% | 4.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
3.5%
EPS terminal req.
$10.44
Spread vs growth
-1.4%
5Y implied EPS CAGR
6.1%
EPS terminal req.
$12.63
Spread vs growth
-3.9%
10Y implied EPS CAGR
8.0%
EPS terminal req.
$20.33
Spread vs growth
-5.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.7%
Start / end P/E
17.7x → 12.5x
EPS bridge
9.20 → 9.40
Residual
-0.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.